QUESTIONSPatent Protection & Lifecycle Management
Venue: Washington Mayflower Hotel
Location: Washington, United States
| Event Date/Time: Feb 23, 2004 | End Date/Time: Feb 24, 2004 |
Report as SpamDescription
The intellectual property landscape has changed dramatically in the past year. The FDA rule change in August, legislation on Capitol Hill, significant case law and the FTC’s Intellectual Property Report are among the developments that biotech and pharmaceutical companies have to consider when formulating strategies to protect their new products and methods.
Against this backdrop of rapid change, the Institute for International Research is pleased to present, Patent Protection & Lifecycle Management, 2004.
On day one, the Honorable James E. Rogan, Under Secretary of Commerce for Intellectual Property, United States Patent and Trademark Office delivers our Keynote Address. Under Secretary Rogan addresses the political dynamics of intellectual property in drug manufacturing, and other issues currently under scrutiny by the USPTO. The day continues with an up-to-the-minute session addressing the latest case law and developments, including any that emerge in the weeks preceding the conference. Among other things, we cover Festo, research tool patents, and partnerships in research collaborations.
On day two, we come fully up-to-date on antitrust concerns. Lead counsel for Upsher-Smith on the Schering-Plough decision presents his case along with other cutting edge cases, and Michael Kades, Staff Attorney at the Federal Trade Commission, examines the Schering-Plough decision from the FTC’s standpoint, and gives us an update on FTC’s Report on Intellectual Property and what it means for patents in pharmaceutical R&D.The FDA’s rule change and generic legislation in Europe are the focus of our final two sessions of the day, and we conclude day two with our popular workshop, Effective Claim Construction Strategies for Improved Patent Lifecy cle Management.
At this event:
The Latest on the FDA Rule Change Implementing the Hatch-Waxman Act
Recent Court Decisions Interpreting Festo and its Impact on the Doctrine of Equivalents
Recent Decisions Regarding the Experimental Use Exemption forUniversities
The Latest Federal Circuit Law Impacting Biotech and PharmaPatents
Making a Business Decision on Freedom to Operate
With an expert speaker faculty comprising top intellectual property experts from leading organizations such as: Johnson & Johnson, Eli Lilly & Company, The US Patent and Trademark Office, Federal Trade Commission , and top IP law firms, Patent Protection and Lifecycle Management, 2004 is designed to equip senior level executives in the innovator pharmaceutical and biotech industry with strategies to protect their intellectual property.
Against this backdrop of rapid change, the Institute for International Research is pleased to present, Patent Protection & Lifecycle Management, 2004.
On day one, the Honorable James E. Rogan, Under Secretary of Commerce for Intellectual Property, United States Patent and Trademark Office delivers our Keynote Address. Under Secretary Rogan addresses the political dynamics of intellectual property in drug manufacturing, and other issues currently under scrutiny by the USPTO. The day continues with an up-to-the-minute session addressing the latest case law and developments, including any that emerge in the weeks preceding the conference. Among other things, we cover Festo, research tool patents, and partnerships in research collaborations.
On day two, we come fully up-to-date on antitrust concerns. Lead counsel for Upsher-Smith on the Schering-Plough decision presents his case along with other cutting edge cases, and Michael Kades, Staff Attorney at the Federal Trade Commission, examines the Schering-Plough decision from the FTC’s standpoint, and gives us an update on FTC’s Report on Intellectual Property and what it means for patents in pharmaceutical R&D.The FDA’s rule change and generic legislation in Europe are the focus of our final two sessions of the day, and we conclude day two with our popular workshop, Effective Claim Construction Strategies for Improved Patent Lifecy cle Management.
At this event:
The Latest on the FDA Rule Change Implementing the Hatch-Waxman Act
Recent Court Decisions Interpreting Festo and its Impact on the Doctrine of Equivalents
Recent Decisions Regarding the Experimental Use Exemption forUniversities
The Latest Federal Circuit Law Impacting Biotech and PharmaPatents
Making a Business Decision on Freedom to Operate
With an expert speaker faculty comprising top intellectual property experts from leading organizations such as: Johnson & Johnson, Eli Lilly & Company, The US Patent and Trademark Office, Federal Trade Commission , and top IP law firms, Patent Protection and Lifecycle Management, 2004 is designed to equip senior level executives in the innovator pharmaceutical and biotech industry with strategies to protect their intellectual property.
